Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Eli Lilly said sales of its blockbuster diabetes treatment, Trulicity, rose 20% from last year to $1.23 billion, but overall revenues missed analysts' forecasts. Eli Lilly & Co. (LLY) posted ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Eli Lilly has doubled its investment in its new Concord manufacturing facility from $1 billion to $2 billion since ...
Eli Lilly’s revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
Eli Lilly reported first-quarter adjusted profit that topped Wall Street's expectations. The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
CAPE CANAVERAL, Fla. — Boeing Co. is now aiming for its first astronaut launch at the beginning of June, after spending the past few weeks struggling with more problems on the space capsule.
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing sales ...